
News|Articles|October 20, 2026
(FAQ) Inflammatory Eye Disease Week: What clinicians should know
Author(s)Sheryl Stevenson
Prevent Blindness marks IED Week, October 19 to 25, as new therapies and pivotal trials reshape care for uveitis and thyroid eye disease.
Advertisement
Advertisement
Prevent Blindness is observing its sixth annual Inflammatory Eye Disease (IED) Week from October 19 to 25, 2026, highlighting
Related to this article

Noab Banoub, a third year medical student, describes his journey into medicine and his view of ophthalmology's future.

The nonprescription 0.125% apraclonidine drop is approved for adults and children 12 years and older, and Alcon says each dose whitens the eye for up to 12 hours.

A higher risk of central serous chorioretinopathy and serous pigment epithelial detachment are associated with varicose veins.

Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.

Two phase 1 OSPREY cohorts of intravitreal STK-002 for ADOA are dosed; first safety and efficacy data are expected by mid-2027.
Advertisement
Advertisement



